Shares of Biodel Inc. moved lower 9/11/08 as concerns continued over the company's late-stage program for the diabetes treatment Viaject. The stock fell 12 cents, or 2.3 percent, to close at $5.14. Shares hit an all-time low of $4.34 over continued concern from Wall Street on the latest late-stage study results for Viaject. The company said Viaject met its goals in a pair of recent trials, but it discounted some of the results from the type 1 diabetes trial. It said those results were markedly different from what was reported in other countries, and they do not appear to be valid. If the results from India are included, the study does not establish that Viaject is at least equivalent to Eli Lilly & Co.'s drug Humulin.

If you are a current shareholder and purchased during period between January 4, 2008 and September 11, 2008 and would like to discuss your options of exercising your rights as a shareholder, please contact us. Please submit the following information so we can determine if you qualify for the suit. If you don't know all the specific details, partial information is also acceptable.